{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:44:44Z","timestamp":1792104284052,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01715-4","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:56:43Z","timestamp":1792101403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Pharmacokinetics of Polmacoxib (CG100649): A Tissue-Selective Dual COX-2 and Carbonic Anhydrase I\/II Inhibitor"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-7891","authenticated-orcid":false,"suffix":"III","given":"Marlon C.","family":"Mallillin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8819-1602","authenticated-orcid":false,"given":"Md Harunur","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6938-4013","authenticated-orcid":false,"given":"Yasmin","family":"Abouelbaqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-1159","authenticated-orcid":false,"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-0213","authenticated-orcid":false,"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-1471","authenticated-orcid":false,"given":"Neal M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"21","key":"1715_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520\u20138. https:\/\/doi.org\/10.1056\/NEJM200011233432103.","journal-title":"N Engl J Med"},{"issue":"10","key":"1715_CR2","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247\u201355. https:\/\/doi.org\/10.1001\/jama.284.10.1247.","journal-title":"JAMA"},{"issue":"11","key":"1715_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa050493.","journal-title":"N Engl J Med"},{"key":"1715_CR4","unstructured":"European Medicines Agency. European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines. European Medicines Agency, London, UK, 2007. https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-withdrawal-marketing-authorisations-lumiracoxib-containing-medicines."},{"issue":"1","key":"1715_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.96.1.272","volume":"96","author":"BF McAdam","year":"1999","unstructured":"McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96(1):272\u20137. https:\/\/doi.org\/10.1073\/pnas.96.1.272.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1715_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-011209-153129","volume":"61","author":"T Grosser","year":"2010","unstructured":"Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquillity: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17\u201333. https:\/\/doi.org\/10.1146\/annurev-med-011209-153129.","journal-title":"Annu Rev Med"},{"issue":"2","key":"1715_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5569\/2278-344X.1089","volume":"13","author":"S Hussain","year":"2024","unstructured":"Hussain S, Ramaswamy S, Mamadapur M, Ajikumar A. Polmacoxib: a drug review. Int J Health Allied Sci. 2024;13(2):68\u201370. https:\/\/doi.org\/10.5569\/2278-344X.1089.","journal-title":"Int J Health Allied Sci."},{"issue":"4","key":"1715_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4055\/cios.2017.9.4.439","volume":"9","author":"M Lee","year":"2017","unstructured":"Lee M, Yoo J, Kim JG, Kyung HS, Bin SI, Kang SB, et al. A randomized, multicenter, Phase III trial to evaluate the efficacy and safety of polmacoxib compared with celecoxib and placebo for patients with osteoarthritis. Clin Orthop Surg. 2017;9(4):439\u201357. https:\/\/doi.org\/10.4055\/cios.2017.9.4.439.","journal-title":"Clin Orthop Surg"},{"issue":"4","key":"1715_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58446","volume":"16","author":"R Easwaran","year":"2024","unstructured":"Easwaran R, Mistry UK, Bhole M, Peethambaran K. Polmacoxib: a review of the newer non-steroidal anti-inflammatory drug in osteoarthritis. Cureus. 2024;16(4):e58446. https:\/\/doi.org\/10.7759\/cureus.58446.","journal-title":"Cureus"},{"key":"1715_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s44337-024-00154-z","volume":"1","author":"S Chandrashekara","year":"2024","unstructured":"Chandrashekara S. A narrative review examining the clinical safety and efficacy of polmacoxib: current evidence and upcoming prospects. Discov Med. 2024;1:129. https:\/\/doi.org\/10.1007\/s44337-024-00154-z.","journal-title":"Discov Med"},{"key":"1715_CR11","unstructured":"Central Drugs Standard Control Organisation (CDSCO). Recommendations of the Subject Expert Committee (Analgesic & Rheumatology) made in its 93rd meeting held on 14 February 2023. New Delhi: CDSCO Headquarters, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; 2023. [cited 2026 Jun 6]. https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Notifications\/Public-Notices\/."},{"issue":"10","key":"1715_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94838","volume":"17","author":"R Verma","year":"2025","unstructured":"Verma R, Gupta R, Waghmare P, Kare SK, Kar AK, Mistry UK, et al. Evaluation of polmacoxib 2 mg for the management of hip and knee osteoarthritis: a prospective, single-arm, multicenter, open-label study. Cureus. 2025;17(10):e94838. https:\/\/doi.org\/10.7759\/cureus.94838.","journal-title":"Cureus"},{"issue":"1","key":"1715_CR13","first-page":"1982","volume":"7","author":"N Madkholkar","year":"2026","unstructured":"Madkholkar N, Sarda K, Sharma A. Safety and effectiveness of polmacoxib in patients with osteoarthritis: a multicenter retrospective real-world study. Int J Med Pharm Res. 2026;7(1):1982\u20136.","journal-title":"Int J Med Pharm Res."},{"key":"1715_CR14","unstructured":"Polmacoxib: CrystalGenomics. AdisInsight drug profile. Cham: Springer Nature; updated 2024 [cited 2026 Jun 6]. Drug ID 800028456. https:\/\/adisinsight.springer.com\/drugs\/800028456."},{"issue":"Suppl 1","key":"1715_CR15","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/S1063-4584(09)60346-0","volume":"17","author":"WK Schmidt","year":"2009","unstructured":"Schmidt WK, Lehnhardt K, Hettwer J, Nadashkevich O, Szombati I, Povoroznyuk V, et al. CG100649, a tissue-specific dual inhibitor of COX-2 and carbonic anhydrase: Phase 2A clinical trial in hip and knee osteoarthritis. Osteoarthritis Cartilage. 2009;17(Suppl 1):S173. https:\/\/doi.org\/10.1016\/S1063-4584(09)60346-0.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"1715_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2016.07.114","volume":"478","author":"HT Kim","year":"2016","unstructured":"Kim HT, Cha H, Hwang KY. Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649). Biochem Biophys Res Commun. 2016;478(1):1\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.114.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1715_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.clinthera.2014.07.007","volume":"37","author":"MJ Kim","year":"2015","unstructured":"Kim MJ, Lim HS, Jin SJ, Jung JA, Noh YH, Kim YH, et al. Pharmacokinetic, pharmacodynamic, and safety\/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a Phase I, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015;37(1):197\u2013210. https:\/\/doi.org\/10.1016\/j.clinthera.2014.07.007.","journal-title":"Clin Ther"},{"issue":"4","key":"1715_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/cpdd.47","volume":"2","author":"S Hirankarn","year":"2013","unstructured":"Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. CG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I\/II: preliminary dose-exposure relationships to define clinical development strategies (NCT00780325). Clin Pharmacol Drug Dev. 2013;2(4):379\u201386. https:\/\/doi.org\/10.1002\/cpdd.47.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"1","key":"1715_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clinthera.2021.11.008","volume":"44","author":"YS Cho","year":"2022","unstructured":"Cho YS, Bae KS, Choi SC, Cho JM, Lim HS. Population PK and pharmacodynamic analysis of polmacoxib in healthy volunteers and patients with osteoarthritis. Clin Ther. 2022;44(1):67\u201380. https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.008.","journal-title":"Clin Ther"},{"issue":"2","key":"1715_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168\u201381. https:\/\/doi.org\/10.1038\/nrd2467.","journal-title":"Nat Rev Drug Discov"},{"key":"1715_CR21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s10973-017-6101-2","volume":"130","author":"SY Kyeon","year":"2017","unstructured":"Kyeon SY, Bang HC, Sohn YT. Solid state of a new COX-2 inhibitor CG100649. J Therm Anal Calorim. 2017;130:1561\u20138. https:\/\/doi.org\/10.1007\/s10973-017-6101-2.","journal-title":"J Therm Anal Calorim"},{"issue":"15","key":"1715_CR22","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1021\/acs.jmedchem.7b00010","volume":"60","author":"AC Flick","year":"2017","unstructured":"Flick AC, Ding HX, Leverett CA, Kyne RE Jr, Liu KKC, Fink SJ, et al. Synthetic approaches to the new drugs approved during 2015. J Med Chem. 2017;60(15):6480\u2013515. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00010.","journal-title":"J Med Chem"},{"issue":"4 Suppl 2","key":"1715_CR23","doi-asserted-by":"publisher","first-page":"P5","DOI":"10.1016\/j.jpain.2008.01.037","volume":"9","author":"C Lee","year":"2008","unstructured":"Lee C, Yang J, Kang S, Seo H, Kim C, Kim S, et al. CG100649, a novel dual-acting COX-2 and carbonic anhydrase inhibitor: preclinical pharmacology [abstract 118]. J Pain. 2008;9(4 Suppl 2):P5.","journal-title":"J Pain"},{"issue":"5","key":"1715_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/14656566.2025.2474574","volume":"26","author":"A Bonardi","year":"2025","unstructured":"Bonardi A, Supuran CT. Polypharmacology of carbonic anhydrase inhibitors and activators. Expert Opin Pharmacother. 2025;26(5):567\u201380. https:\/\/doi.org\/10.1080\/14656566.2025.2474574.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1715_CR25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/clpt.2012.3","volume":"91","author":"C Skarke","year":"2012","unstructured":"Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, FitzGerald GA. Comparative impact on prostanoid biosynthesis of celecoxib and the novel non-steroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012;91(6):986\u201393. https:\/\/doi.org\/10.1038\/clpt.2012.3.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1715_CR26","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.clinthera.2014.09.024","volume":"36","author":"C Skarke","year":"2014","unstructured":"Skarke C, FitzGerald GA. Selective COX-2 inhibitors suppress prostacyclin. Clin Ther. 2014;36(12):2120\u20131. https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.024.","journal-title":"Clin Ther"},{"issue":"1","key":"1715_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clinthera.2013.12.004","volume":"36","author":"HY Choi","year":"2024","unstructured":"Choi HY, Jin SJ, Jung JA, Kim UJ, Ko YJ, Noh YH, et al. Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. Clin Ther. 2024;36(1):115\u201325. https:\/\/doi.org\/10.1016\/j.clinthera.2013.12.004.","journal-title":"Clin Ther"},{"key":"1715_CR28","unstructured":"Acelex (polmacoxib): prescribing information. Seoul: CrystalGenomics Inc.; 2015 [cited 2026 Jun 6]. Republic of Korea Ministry of Food and Drug Safety drug-product database (drug code 201501324)."},{"issue":"2","key":"1715_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1021\/tx800415j","volume":"22","author":"DA Smith","year":"2009","unstructured":"Smith DA, Obach RS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol. 2009;22(2):267\u201379. https:\/\/doi.org\/10.1021\/tx800415j.","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"1715_CR30","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1124\/dmd.113.053850","volume":"41","author":"H Gao","year":"2013","unstructured":"Gao H, Krausz KW, Idle JR, Gonzalez FJ. Meeting report: metabolites in safety testing (MIST): considerations and challenges in metabolite identification and quantification. Drug Metab Dispos. 2013;41(12):2055\u20139. https:\/\/doi.org\/10.1124\/dmd.113.053850.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1715_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00008571-200104000-00006","volume":"11","author":"C Tang","year":"2001","unstructured":"Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics. 2001;11(3):223\u201335. https:\/\/doi.org\/10.1097\/00008571-200104000-00006.","journal-title":"Pharmacogenetics"},{"key":"1715_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/JPR.S75160","volume":"8","author":"K Brune","year":"2015","unstructured":"Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105\u201318. https:\/\/doi.org\/10.2147\/JPR.S75160.","journal-title":"J Pain Res"},{"key":"1715_CR33","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/DDDT.S464485","volume":"18","author":"YH Wang","year":"2024","unstructured":"Wang YH, Zhu LL, Li TL, Zhou Q. Imrecoxib: advances in pharmacology and therapeutics. Drug Des Devel Ther. 2024;18:1711\u201325. https:\/\/doi.org\/10.2147\/DDDT.S464485.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1715_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","volume":"38","author":"NM Davies","year":"2000","unstructured":"Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38(3):225\u201342. https:\/\/doi.org\/10.2165\/00003088-200038030-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"26","key":"1715_CR35","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, L\u00fcscher TF, Libby P, Husni ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1611593.","journal-title":"N Engl J Med"},{"issue":"9549","key":"1715_CR36","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(06)69666-9.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"1715_CR37","first-page":"291","volume":"69","author":"J Cabrera","year":"2010","unstructured":"Cabrera J, Schmidt WK, Cho JM, Ro S, Singh G. Pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of CG100649, a dual COX-2 and carbonic anhydrase inhibitor, in primary osteoarthritis of the hip or knee [abstract THU0442]. Ann Rheum Dis. 2010;69(Suppl 3):291.","journal-title":"Ann Rheum Dis"},{"key":"1715_CR38","unstructured":"CrystalGenomics, Inc. A double-blind, placebo-controlled, Phase II study of CG100649 for primary osteoarthritis in male subjects [NCT00530452]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine; updated 2008. [cited 2026 Jun 6]. https:\/\/clinicaltrials.gov\/study\/NCT00530452."},{"key":"1715_CR39","unstructured":"CrystalGenomics Inc. A double-blind, randomized, multicenter, noninferiority, Phase II repeat-dose study of CG100649 versus celecoxib in osteoarthritis patients [NCT01341405]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. [cited 2026 Jun 6]. https:\/\/clinicaltrials.gov\/study\/NCT01341405."},{"issue":"9","key":"1715_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/17581869.2024.2427944","volume":"14","author":"SD Sinha","year":"2024","unstructured":"Sinha SD, Prasad TB, Konatham B, Sriramadasu SC, Karmakar A, Sharma AK, et al. Polmacoxib 2 mg in patients with mild to moderate idiopathic osteoarthritis of hip\/knee: a randomized, double-anonymous study. Pain Manag. 2024;14(9):497\u2013506. https:\/\/doi.org\/10.1080\/17581869.2024.2427944.","journal-title":"Pain Manag"},{"issue":"4-S","key":"1715_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.22270\/jddt.v11i4-S.4984","volume":"11","author":"A Chaudhary","year":"2021","unstructured":"Chaudhary A, Dhaiya M, Tyagi S, Mittal S. Method development and validation of polmacoxib in capsule dosage form by RP-HPLC. J Drug Deliv Ther. 2021;11(4-S):59\u201363. https:\/\/doi.org\/10.22270\/jddt.v11i4-S.4984.","journal-title":"J Drug Deliv Ther"},{"issue":"3","key":"1715_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmag006","volume":"64","author":"H Thumbar","year":"2026","unstructured":"Thumbar H, Dhaduk B. Development and validation of reverse phase high-performance liquid chromatographic method enabling simultaneous estimation of polmacoxib and its process-related impurities: exploring degradation pathways and elucidating degradant structures via LC\u2013MS\/MS and NMR spectroscopy. J Chromatogr Sci. 2026;64(3):bmag006. https:\/\/doi.org\/10.1093\/chromsci\/bmag006.","journal-title":"J Chromatogr Sci"},{"issue":"23","key":"1715_CR43","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1080\/17576180.2025.2601870","volume":"17","author":"A Sohani","year":"2025","unstructured":"Sohani A, Debaje S, Guleria K, Sankulkar S, Gupta K, Bandi BMR, et al. Bioanalytical method development for polmacoxib in rat plasma using LC\u2013MS\/MS and its preclinical pharmacokinetic evaluation. Bioanalysis. 2025;17(23):1561\u20138. https:\/\/doi.org\/10.1080\/17576180.2025.2601870.","journal-title":"Bioanalysis"},{"key":"1715_CR44","unstructured":"CrystalGenomics Inc. A randomized, open-label, multiple-dose, parallel study to compare the pharmacokinetics and to evaluate drug\u2013drug interaction of CG100650 (polmacoxib + tramadol) in healthy volunteers [NCT03775629]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine; updated 2019. [cited 2026 Jun 6]. https:\/\/clinicaltrials.gov\/study\/NCT03775629."},{"issue":"10","key":"1715_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.59556\/japi.73.1180","volume":"73","author":"VS Gunjal","year":"2025","unstructured":"Gunjal VS, Pawar RR, Sharma AD. Review of safety and efficacy of polmacoxib: a novel dual inhibitor of cyclo-oxygenase 2 and carbonic anhydrase in osteoarthritis and acute painful conditions. J Assoc Physicians India. 2025;73(10):88\u201392. https:\/\/doi.org\/10.59556\/japi.73.1180.","journal-title":"J Assoc Physicians India"},{"key":"1715_CR46","unstructured":"Sungkyunkwan University School of Medicine. Perioperative polmacoxib reduces opioid consumption for postoperative pain after rotator cuff tear [NCT06590714]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine; updated 2024 Sep. [cited 2026 Jun 6]. https:\/\/clinicaltrials.gov\/study\/NCT06590714."},{"issue":"3","key":"1715_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17425255.2024.2328152","volume":"20","author":"CT Supuran","year":"2024","unstructured":"Supuran CT. Drug interactions of carbonic anhydrase inhibitors and activators. Expert Opin Drug Metab Toxicol. 2024;20(3):143\u201355. https:\/\/doi.org\/10.1080\/17425255.2024.2328152.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1715_CR48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3393\/ac.2019.08.17","volume":"37","author":"IG Song","year":"2021","unstructured":"Song IG, Jung KU, Kim HO, Kim H, Chun HK. An unusual case of colon perforation with multiple transmural ulcers after use of polmacoxib and everolimus in a metastatic breast cancer patient. Ann Coloproctol. 2021;37(2):120\u20134. https:\/\/doi.org\/10.3393\/ac.2019.08.17.","journal-title":"Ann Coloproctol"},{"key":"1715_CR49","unstructured":"International Council for Harmonisation. ICH guideline M10 on bioanalytical method validation and study sample analysis [Internet]. Geneva: ICH; 2022. [cited 2026 Jun 6]. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines"},{"issue":"6","key":"1715_CR50","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10637-014-0144-z","volume":"32","author":"SH Kim","year":"2014","unstructured":"Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, et al. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs. 2014;32(6):1105\u201312. https:\/\/doi.org\/10.1007\/s10637-014-0144-z.","journal-title":"Invest New Drugs"},{"issue":"Suppl 1","key":"1715_CR51","doi-asserted-by":"publisher","DOI":"10.2337\/db24-906-P","volume":"73","author":"A Gautam","year":"2024","unstructured":"Gautam A, Agrawal PK, Pursnani N, Yadav SK, Yadav A. 906-P: Safety and efficacy of polmacoxib for diabetes-associated frozen shoulder: prospective randomized control trial. Diabetes. 2024;73(Suppl 1):906\u2013P. https:\/\/doi.org\/10.2337\/db24-906-P.","journal-title":"Diabetes"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01715-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:56:46Z","timestamp":1792101406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01715-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":51,"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01715-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Neal M. Davies is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative literature review and did not involve new research on human participants or animals by the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All sources cited are available from the publishers indicated in the reference list and from the Protein Data Bank (5GMM, 5GMN) and the ClinicalTrials.gov registry (numbers cited).","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No original datasets or custom analysis code were generated by the authors for this narrative review.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally to all aspects of this work. In accordance with the CRediT (Contributor Roles Taxonomy), all authors contributed equally to conceptualisation, methodology, investigation, data curation, formal analysis, visualisation, writing of the original draft, and writing, reviewing, and editing. All authors read and approved the final version of the manuscript for submission.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}